Sanofi Urges Fed. Circ. To Deny Amgen's Redo Bid In IP Row
Sanofi SA on Tuesday urged the Federal Circuit to stand by its October decision reviving a challenge to Amgen Inc.'s cholesterol medication Repatha, arguing that the panel didn't stray from the...To view the full article, register now.
Already a subscriber? Click here to view full article